Physician profile
Patrick Smith
NPI 1831758044
$8,504.12
in general payments reported to CMS, 2019-2025
40 companies · $2,443 in 2025
The $2,443 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $1,388 · 2023: $2,171 · 2024: $2,148 · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,761.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,484.72 | 2021-2025 | |
| Lilly USA, LLC | $763.54 | 2022-2025 | Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $718.20 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $647.31 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Teva Pharmaceuticals USA, INC. | $520.22 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $459.47 | 2023-2025 | |
| Amgen INC. | $372.74 | 2021-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.50 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $325.32 | 2022-2025 | Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $320.14 | 2022-2024 | Auvelity, Sunosi |
| Astellas Pharma US INC | $300.37 | 2022-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $277.53 | 2023-2025 | Rexulti, Nuedexta |
| Collegium Pharmaceutical, INC. | $226.26 | 2022-2025 | Xtampza, Belbuca |
| Kowa Pharmaceuticals America, INC. | $190.70 | 2021-2024 | Seglentis, Livalo, Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.69 | 2021-2025 | Caplyta |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $166.89 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $123.17 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $107.11 | 2024 | Voquezna |
| Almatica Pharma LLC | $94.80 | 2023-2024 | Loreev Xr, Gralise |
| Bayer Healthcare Pharmaceuticals INC. | $91.46 | 2024-2025 | |
| Lundbeck LLC | $84.77 | 2022-2025 | Rexulti |
| Urovant Sciences INC | $67.03 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $60.91 | 2021-2025 | Spravato |
| Xeris Pharmaceuticals, INC. | $60.87 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.14 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.02 | 2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $51.79 | 2021-2025 | Belsomra, Capvaxive, Gardasil 9 |
| Corium, LLC | $49.01 | 2023 | Azstarys |
| Indivior INC. | $48.17 | 2024 | Sublocade |
| Hologic Sales and Service, LLC | $46.91 | 2024 | Aptima |
| Paratek Pharmaceuticals, INC. | $35.43 | 2021 | |
| Neurocrine Biosciences, INC. | $34.03 | 2022-2023 | Ingrezza |
| Verona Pharma, INC. | $31.68 | 2025 | Ohtuvayre |
| Ultragenyx Pharmaceutical INC. | $18.96 | 2023 | Crysvita |
| Braeburn INC. | $17.91 | 2025 | Brixadi |
| Harmony Biosciences LLC | $16.79 | 2025 | |
| Sobi, INC | $15.96 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.15 | 2023 | Quviviq |
| Dexcom, INC. | $15.04 | 2021 | |
| Amarin Pharma, INC. | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.